Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, HEALTH, Conference Calls/ Webcasts

Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference


VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16-17, 2024.

Company Presentation Details:

Date:		 
Tuesday, April 16, 2024

Time:		 
9:30 AM Eastern Time

Webcast:		 
Register here

Presenters:		 
Ian Mortimer, President and Chief Executive Officer
 

A live webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. For more information, please visit www.xenon-pharma.com.

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
[email protected]

For Media:
Jodi Regts
Xenon Corporate Affairs
(604) 484-3353
[email protected]



These press releases may also interest you

at 09:53
Starlight Cardiovascular Awarded $2M NIH SBIR Phase II Grant to Develop Pediatric Cardiology Device
Starlight Cardiovascular, Inc., a company developing pediatric cardiovascular medical devices, announced that it has been awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Heart, Lung, and Blood Institute (NHLBI) of...

at 09:47
Traverse Biotech Awarded Phase I SBIR Grant by the National Institute of Allergy and Infectious Diseases for Development of Innate Immune Stimulator
Traverse Biotech, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. This grant will support the development of our oral innate...

at 09:45
National Organization for Rare Disorders (NORD) Names Pamela K. Gavin as CEO
The National Organization for Rare Disorders (NORD) announced today that Pamela K. Gavin has been named CEO, effective immediately. She succeeds Peter L. Saltonstall, who announces his retirement and served as President and CEO since 2008. After a...

at 09:45
People Think They Know More about Stroke Warning Signs than They Actually Do According to a New MedStar Health Survey
A survey conducted by MedStar Health found people could be overly confident about their ability to recognize the serious warning signs of someone having a stroke. The national survey of 1000 people found 64% of respondents said they were "confident"...

at 09:42
Perrigo Announces Quarterly Dividend
Perrigo Company plc , a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024....

at 09:38
Empower Pharmacy Unveils Brand Refresh, Signifying the Next Era of Growth and Innovation During Boon of Consumer Driven Telehealth Care
Empower Pharmacy, the country's most advanced compounding pharmacy, today announced a significant milestone with the launch of its brand refresh, signaling the start of a new chapter aimed at enhancing healthcare accessibility and elevating patient,...

More news about Health...


News published on and distributed by: